Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: Last September, the company filed a lawsuit against the FDA and U.S. Department of Health and Human Services, challenging testing guidelines used for evaluating generic drugs. A federal district court dismissed the motion last Friday on grounds that it lacked standing.
Now what: The lawsuit addressed the regulatory process concerning ViroPharma's Vancocin antibiotic, which effectively salvaged the company in 2005. Its dismissal appears to increase the competitive threat from generic-drug makers. Despite expectations that EPS will decline in 2011, the stock hit a new 52-week high last Friday, suggesting investors were betting on a more favorable outcome to the lawsuit.
Interested in more info on ViroPharma? Add it to your watchlist by clicking here.
Fool contributor Cindy Johnson does not own shares of any company named above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.